ReviewJournal of market access & health policy2021
Accelerating patient access to oncology medicines with multiple indications in Europe.
Review in Journal of market access & health policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pricing Combination Therapies: A Systematic Review of Value Attribution, Cost-Sharing Mechanisms and Policy Frameworks.Applied health economics and health policy · 2026Pooled it
- Balancing Access and Value in Multi-Indication Medicines: Implications of PD-(L)1 Broad Listings in Australia.PharmacoEconomics · 2026Review
- A natural language processing approach to determine whether streamlined health technology assessment for multi-indication medicines is feasible.PLOS digital health · 2026Article
- Beyond Indication Expansion: Aligning Evidence, Reimbursement, and Access in Multi-Indication Oncology Drugs [Letter].Drug design, development and therapy · 2026Article
- Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025).Healthcare (Basel, Switzerland) · 2025Article
- Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience.Journal of comparative effectiveness research · 2025Review
- Pricing for Multi-Indication Drugs in the Italian Regulatory Context.PharmacoEconomics - open · 2025Article
- Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?Journal of market access & health policy · 2025Article
- How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.BMJ public health · 2024Article
- A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries.Future oncology (London, England) · 2024Article
- Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe.Applied health economics and health policy · 2023Review
- The challenges of access to innovative medicines with limited evidence in the European Union.Frontiers in pharmacology · 2023Review
- Association of exogenous factors with the access to innovative pharmaceutical products in Hungary.PloS one · 2023Article
- Not one, but many: developing a multi-indication pricing model for medicines in Belgium.Frontiers in pharmacology · 2023Article
- Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.BMC health services research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.